A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, 2-ARM STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF EFIMOSFERMIN ALFA INJECTION IN ADULT PARTICIPANTS WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (NEBULA-1)
- Registry ID
- 306300
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Last update
- 2026-07-21
Conditions
- CIRRHOSIS OF THE LIVER
- METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Related clinical trials
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH KNOWN OR SUSPECTED F2- OR F3-STAGE METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) (ZENITH-2)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH BIOPSY-CONFIRMED F2- OR F3-STAGE METABOLIC DYSFUNCTION-ASSOCIATED BOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) (ZENITH-1)
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFECT OF SELADELPAR ON CLINICAL OUTCOMES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND COMPENSATED CIRRHOSIS
- A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL TO EVALUATE LIVER-RELATED CLINICAL OUTCOMES AND SAFETY OF ONCE WEEKLY INJECTED SURVODUTIDE IN PARTICIPANTS WITH COMPENSATED NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (NASH/MASH) CIRRHOSIS
- A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS
WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS (MASH)
- A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF EFINOPEGDUTIDE (MK-6024) IN ADULTS WITH
COMPENSATED CIRRHOSIS SECONDARY TO METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS
View on source registry